Enrico Martin

180 Chapter 7 63. Payne R, Mrowczynski OD, Slagle- Webb B, et al. MLN8237 treatment in an orthoxenograft murine model for malignant peripheral nerve sheath tumors. J Neurosurg. February 2018:1-11. doi:10.3171/2017.8.JNS17765 64. Perez M, Munoz-Galvan S, Jimenez-Garcia MP, Marin JJ, Carnero A. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget. 2015;6(38):40557-40574. doi:10.18632/oncotarget.5829 65. Zhang P, Yang X, Ma X, et al. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer. 2015;14:55. doi:10.1186/s12943-015-0325-1 66. Nair JS, Musi E, Schwartz GK. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IkappaB and Downregulation of Survivin. Clin Cancer Res. 2017;23(15):4301-4311. doi:10.1158/1078-0432.CCR-16-2632 67. Dickson MA, Mahoney MR, Tap WD, et al. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(10):1855- 1860. doi:10.1093/annonc/mdw281 68. Liu T-C, Zhang T, Fukuhara H, et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006;14(6):789-797. doi:10.1016/j.ymthe.2006.07.011 69. Liu T-C, Zhang T, Fukuhara H, et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res. 2006;12(22):6791-6799. doi:10.1158/1078-0432.CCR-06-0263 70. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther. 2007;15(2):279-286. doi:10.1038/ sj.mt.6300038 71. Mahller YY, Sakthivel B, Baird WH, et al. Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. Cancer Gene Ther. 2008;15(11):733-741. doi:10.1038/cgt.2008.40 72. Maldonado AR, Klanke C, Jegga AG, et al. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med. 2010;12(7):613-623. doi:10.1002/jgm.1479 73. Antoszczyk S, Spyra M, Mautner VF, et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 2014;16(8):1057-1066. doi:10.1093/ neuonc/not317 74. Currier MA, Sprague L, Rizvi TA, et al. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. Oncotarget. 2017;8(11):17412-17427. doi:10.18632/ oncotarget.14885 75. Deyle DR, Escobar DZ, Peng K-W, Babovic-Vuksanovic D. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. Gene. 2015;565(1):140-145. doi:10.1016/j. gene.2015.04.001 76. Patel A V, Johansson G, Colbert MC, Dasgupta B, Ratner N. Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors. Neuro Oncol. 2015;17(12):1599- 1608. doi:10.1093/neuonc/nov076 77. Demestre M, Terzi MY, Mautner V, Vajkoczy P, Kurtz A, Pina AL. Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs). J Neurooncol. 2013;115(3):391-399. doi:10.1007/s11060- 013-1252-x